Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 3Glioblastoma 2Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Muscle-invasive Urothelial Cancer of the Bladder 1Mouth Neoplasms 1Melanoma 1Laryngeal Neoplasms 1Craniopharyngioma 1Carcinoma 1Brain Neoplasms 1

Interventions

Cisplatin 18Specimen Handling 10Radiotherapy 10Cetuximab 10Magnetic Resonance Spectroscopy 9Radiotherapy, Intensity-Modulated 8Carboplatin 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6Platinum 6Paclitaxel 5Drug Therapy 5Celecoxib 5cemiplimab 4X-Rays 4Surgical Procedures, Operative 4Radiation 4Fluorouracil 4Biopsy 4Taxes 3Standard of Care 3Docetaxel 3durvalumab 2Radiotherapy, Image-Guided 2RRx-001 2Practice Guidelines as Topic 2Observation 2Nivolumab 2Injections 2Fenretinide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mouth Neoplasms × Transurethral Resection of Bladder × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡